Slide Resources

Here, you can search through all the slide resources available on this website: slide-sets from Meeting ResourcesESMO E-Learning modules; and Educational Slides.




Format available

http://oncologypro.esmo.org/Meeting-Resourc...-5461-in-Patients-with-Advanced-Solid-Tumors

G-quadruplexes are secondary DNA structures that reversibly form in guanine-rich regions that can lead to replication fork collapse and double-stranded DNA breaks.

Date: 06 Mar 2018
Section: Meeting Resources
Topic: Anti-Cancer Agents & Biologic Therapy

http://oncologypro.esmo.org/Meeting-Resourc...ginine-Deprivation-in-ASS1-Deficient-Cancers

Argininosuccinate Synthetase 1 (ASS1) is silenced in ∼90% of sarcomas. Loss of this urea cycle enzyme causes cells to become dependent upon extracellular arginine for continued cell growth and proliferation.

Date: 06 Mar 2018
Section: Meeting Resources
Topic: Palliative and Supportive Care

http://oncologypro.esmo.org/Meeting-Resourc...-cell-metabolism-and-metabolic-reprogramming

Date: 06 Mar 2018
Section: Meeting Resources

http://oncologypro.esmo.org/Meeting-Resourc...ays-to-harness-targeting-DNA-to-treat-cancer

Date: 06 Mar 2018
Section: Meeting Resources
Topics: Biomarkers, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...cer-Therapies/Novel-topoisomerase-inhibitors

DNA topoisomerases are validated targets for a broad range of widely used anticancer drugs. They include the topoisomerase II (TOP2) inhibitors, etoposide, teniposide, doxorubicin, daunorubicin and...

Date: 06 Mar 2018
Section: Meeting Resources

http://oncologypro.esmo.org/Meeting-Resourc...-and-immunotherapy-Synergies-of-combinations

In cancer the presence of T cell immune infiltration has been recognised as a prognostic factor, however the mechanisms underpinning this response are not clearly defined.

Date: 06 Mar 2018
Section: Meeting Resources
Topic: Cancer Immunology and Immunotherapy

http://oncologypro.esmo.org/Meeting-Resourc...of-CDK4-6-inhibition-Induction-of-senescence

CDK4/6 inhibitors are being used to treat a variety of human malignancies. In well-differentiated (WDLS) and dedifferentiated (DDLS) liposarcoma we had previously suggested that their clinical promise...

Date: 07 Mar 2018
Section: Meeting Resources

http://oncologypro.esmo.org/Meeting-Resourc...ted-Anticancer-Therapies/Why-is-PI3K-so-hard

Hyperactivation of the PI3K-AKT-mTOR signaling cascade occurs in a plethora of cancer types. Both preclinical data and clinical studies suggest that this pathway is a valid pharmacological target in selected patient populations.

Date: 07 Mar 2018
Section: Meeting Resources

http://oncologypro.esmo.org/Meeting-Resourc...frica-2018/Current-Standard-of-Care-of-NSCLC

Date: 12 Mar 2018
Section: Meeting Resources

http://oncologypro.esmo.org/Meeting-Resourc...rica-2018/Case-Presentation-Metastatic-NSCLC

Date: 12 Mar 2018
Section: Meeting Resources